These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21904216)

  • 21. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.
    Thakur A; Norkina O; Lum LG
    Cancer Immunol Immunother; 2011 Dec; 60(12):1707-20. PubMed ID: 21713642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
    Märkl F; Benmebarek MR; Keyl J; Cadilha BL; Geiger M; Karches C; Obeck H; Schwerdtfeger M; Michaelides S; Briukhovetska D; Stock S; Jobst J; Müller PJ; Majed L; Seifert M; Klüver AK; Lorenzini T; Grünmeier R; Thomas M; Gottschlich A; Klaus R; Marr C; von Bergwelt-Baildon M; Rothenfusser S; Levesque MP; Heppt MV; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
    Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
    Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro.
    Hideshima T; Iwasaki A; Baba M; Yamashita Y; Shirakusa T; Okada H
    Surg Today; 1996; 26(2):83-8. PubMed ID: 8919276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
    Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
    Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
    Haas C; Krinner E; Brischwein K; Hoffmann P; Lutterbüse R; Schlereth B; Kufer P; Baeuerle PA
    Immunobiology; 2009; 214(6):441-53. PubMed ID: 19157637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
    Cioffi M; Dorado J; Baeuerle PA; Heeschen C
    Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.
    Campoli MR; Chang CC; Kageshita T; Wang X; McCarthy JB; Ferrone S
    Crit Rev Immunol; 2004; 24(4):267-96. PubMed ID: 15588226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
    Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
    Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
    Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
    Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
    Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
    Haagen IA; de Lau WB; Bast BJ; Geerars AJ; Clark MR; de Gast BC
    Cancer Immunol Immunother; 1994 Dec; 39(6):391-6. PubMed ID: 7528094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.
    Pfosser A; Brandl M; Salih H; Grosse-Hovest L; Jung G
    Int J Cancer; 1999 Feb; 80(4):612-6. PubMed ID: 9935165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity.
    Maletz K; Kufer P; Mack M; Raum T; Pantel K; Riethmüller G; Gruber R
    Int J Cancer; 2001 Aug; 93(3):409-16. PubMed ID: 11433407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.